All News

Kelsea Seago, PharmD, discusses the crucial role of pharmacists in managing chimeric antigen receptor (CAR) T-cell therapy resistance.

Building off the positive results of ELM-1, the ELM-2 trial found intravenously administered odronextamab was safe and effective in patients with relapsed or refractory follicular lymphoma.

The supplemental biologics license application was granted based on results from the ADRIATIC phase 3 trial among individuals with limited stage small cell lung cancer.

The decision is based positive data from the Deltacel-01 clinical trial.

AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.

This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

Some individuals are still unaware of the significance of routine oral hygiene and its link to overall health

Tune into this episode of “Public Health Matters” to learn about how Healthcare Advocate Summit, created by advocates for advocates, is involved in the discussion on improving access to health care.

Axatilimab-csfr (Niktimvo, Incyte Corporation) is a colony stimulating factor-1 receptor-blocking antibody for the treatment of chronic graft-versus-host disease (cGVHD).

The decision is based on clinical findings demonstrating seladelpar’s ability to effectively regulate of alkaline phosphatase values in patients.

Response to intravenous immunoglobulin treatment and analysis of neurofilament light chains in patients could be used as prognostic indicators of Guillain-Barre syndrome.

Individuals with Parkinson disease reported a decrease in bacterial genes for biosynthesis of riboflavin (vitamin B2) and biotin (vitamin B7).

The seroprotection rate of antibody titers was 100% against the 3 viruses, and geometric mean titer also increased from administration to day 43.

Predicting disease progression is essential to improve the health outcomes of patients with multiple sclerosis.

Roszak highlighted pharmacy data interoperability and food is medicine programs as 2 examples of innovative projects at the National Association of Chain Drug Stores.

Pharmacists play a vital role in therapy selection.

Patient fears can be mitigated by pharmacists who use targeted communication strategies to bolster acceptance.

The data builds off prior studies supporting bendamustine-rituximab as a first-line treatment for patients with non-Hodgkin lymphoma.

In recent years, telestroke services have transformed stroke care delivery, especially in rural or underserved areas.

Pharmacists play an important role in managing patients with this complex condition.

Community accessibility and specialized training in effective medication counseling make pharmacists a valuable resource in helping address injectable biologic hesitancy.

The authors determined that 40 patients (74.1%) converted from chronic to episodic migraine.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

The treatment is indicated to improve and maintain visual acuity in individuals with neovascular age-related macular degeneration.

In her first Editor’s Note as editor in chief of PPFO, Zahra Mahmoudjafari shares reflections on a summer filled with conferences.

Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, which drives disease mechanisms in prurigo nodularis.

Remind parents that routine exams, immunizations, and nutrition are crucial to helping children succeed.

The autologous, fully human CD19 chimeric antigen receptor T-cell product, KYV-101, is being studied for the treatment of patients with progressive myasthenia gravis.

The trial evaluated a fixed-dose combination of vibostolimab and pembrolizumab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.